Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
March 06, 2024 08:00 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
March 05, 2024 16:30 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
January 08, 2024 07:00 ET
|
Werewolf Therapeutics, Inc.
- Prioritizing development of wholly owned clinical assets, WTX-124 and WTX-330; key updates from both INDUKINETM programs anticipated in 2024 - - WTX-124: updated interim monotherapy...
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
January 04, 2024 16:05 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
November 22, 2023 07:00 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 14, 2023 16:25 ET
|
Werewolf Therapeutics, Inc.
– Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of dose-dependent anti-tumor and biomarker activity – ...
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
November 03, 2023 07:00 ET
|
Werewolf Therapeutics, Inc.
Preliminary data on WTX-124 provide compelling early evidence of dose-dependent biomarker and antitumor activity in patients with advanced or metastatic solid tumors relapsed or refractory to standard...
Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
October 31, 2023 09:00 ET
|
Werewolf Therapeutics, Inc.
Interim, first-in-human clinical results from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124 including safety and preliminary antitumor activity to be described in...
Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 27, 2023 09:00 ET
|
Werewolf Therapeutics, Inc.
Six abstracts, spanning Werewolf’s PREDATOR™ platform and INDUKINE™ pipeline, accepted for poster presentations at SITC annual meetingCompany to present interim first-in-human clinical data from...
Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124
September 11, 2023 16:05 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...